Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6819-6827

  Cheng, Mu ^a   Huang, Johnny X ^a   Ramu, Soumya ^a   Butler, Mark S ^a   Cooper, Matthew A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOLYTE; NISIN; RAMOPLANIN; TEICOPLANIN; VANCOMYCIN; ANION; ANTIINFECTIVE AGENT; DEPSIPEPTIDE; PROTEIN BINDING;

ARTICLE; BACTERIAL CELL; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BINDING AFFINITY; CELL MEMBRANE DEPOLARIZATION; CELL STRUCTURE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; LIPID MEMBRANE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHOSPHOLIPID BILAYER; TRANSMISSION ELECTRON MICROSCOPY; CELL MEMBRANE; CELL SURVIVAL; CELL WALL; CHEMISTRY; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIONS; ANTI-BACTERIAL AGENTS; CELL MEMBRANE; CELL SURVIVAL; CELL WALL; DEPSIPEPTIDES; MICROBIAL SENSITIVITY TESTS; NISIN; PROTEIN BINDING; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 84908276445     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00061-14     Document Type: Article

References (73)

1. Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. 1984. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physicochemical characteristics. J. Antibiot. (Tokyo) 37:309-317.
2. Parenti F, Ciabatti R, Cavalleri B, Kettenring J. 1990. Ramoplanin: a review of its discovery and its chemistry. Drugs Exp. Clin. Res. 16:451-455.
3. Reynolds PE, Somner EA. 1990. Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp. Clin. Res. 16:385-389.
4. Somner EA, Reynolds PE. 1990. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 34:413-419. http://dx.doi.org/10.1128/AAC.34.3.413.
5. Lo MC, Men H, Branstrom A, Helm J, Yao N, Goldman R, Walker S. 2000. A new mechanism of action proposed for ramoplanin. J. Am. Chem. Soc. 122:3540-3541. http://dx.doi.org/10.1021/ja000182x.
6. Hu YN, Helm JS, Chen L, Ye XY, Walker S. 2003. Ramoplanin inhibits bacterial transglycosylases by binding as a dimer to lipid II. J. Am. Chem. Soc. 125:8736-8737. http://dx.doi.org/10.1021/ja035217i.
7. Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S. 2006. The mechanism of action of ramoplanin and enduracidin. Mol. Biosyst. 2:69-76. http://dx.doi.org/10.1039/b515328j.
8. Mobarakai N, Quale JM, Landman D. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387. http://dx.doi.org/10.1128/AAC.38.2.385.
9. Ristow TA, Noskin GA, Warren JR, Peterson LR. 1995. In vitro activity of RP 59500 (quinupristin dalfopristin) and ramoplanin against vanco-mycin-resistant Enterococcus faecium. Microb. Drug Resist. 1:335-339. http://dx.doi.org/10.1089/mdr.1995.1.335.
10. McCafferty DG, Cudic P, Frankel BA, Barkallah S, Kruger RG, Li WK. 2002. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 66:261-284. http://dx.doi.org/10.1002/bip.10296.
11. Farver DK, Hedge DD, Lee SC. 2005. Ramoplanin: a lipoglycodepsipeptide antibiotic. Ann. Pharmacother. 39:863-868. http://dx.doi.org/10.1345/aph.1E397.
12. Johnson CC, Taylor S, Pitsakis P, May P, Levison ME. 1992. Bactericidal activity of ramoplanin against antibiotic-resistant enterococci. Antimicrob. Agents Chemother. 36:2342-2345. http://dx.doi.org/10.1128/AAC.36.10.2342.
13. Montecalvo MA. 2003. Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in highrisk patients. J. Antimicrob. Chemother. 51:iii31-iii35. http://dx.doi.org/10.1093/jac/dkg274.
14. Walker S, Chen L, Hu YN, Rew Y, Shin DW, Boger DL. 2005. Chemistry and biology of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. Chem. Rev. 105:449-475. http://dx.doi.org/10.1021/cr030106n.
15. Fulco P, Wenzel RP. 2006. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev. Anti Infect. Ther. 4:939-945. http://dx.doi.org/10.1586/14787210.4.6.939.
16. Gerding DN, Muto CA, Owens RC, Jr. 2008. Treatment of Clostridium difficile infection. Clin. Infect. Dis. 46:S32-S42. http://dx.doi.org/10.1086/521860.
17. Pallanza R, Berti M, Scotti R, Randisi E, Arioli V. 1984. A-16686, a new antibiotic from Actinoplanes. II. Biological properties. J. Antibiot. (Tokyo) 37:318-324. http://dx.doi.org/10.7164/antibiotics.37.318.
18. Jabes D, Brunati C, Candiani G, Riva S, Romanó G, Maffioli S, Rossi R, Simone M, Gaspari E, Donadio S. 2014. Pharmacological properties of NAI-603, a well-tolerated semisynthetic derivative of ramoplanin. Antimicrob. Agents Chemother. 58:1922-1929. http://dx.doi.org/10.1128/AAC.01620-13.
19. Landman D, Quale JM, Burney S, Kreiswirth B, Willey BM. 1996. Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin. J. Antimicrob. Chemother. 37:323-329. http://dx.doi.org/10.1093/jac/37.2.323.
20. Van Bambeke F. 2006. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr. Opin. Investig. Drugs 7:740-749.
21. NanoTherapeutics Inc. 2014. Products: NTI-851 (Ramoplanin™). http://www.nanotherapeutics.com/ramoplanin/.
22. Helm JS, Chen L, Walker S. 2002. Rethinking ramoplanin: the role of substrate binding in inhibition of peptidoglycan biosynthesis. J. Am. Chem. Soc. 124:13970-13971. http://dx.doi.org/10.1021/ja021097n.
23. O'Shea R, Moser HE. 2008. Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem. 51:2871-2878. http://dx.doi.org/10.1021/jm700967e.
24. Greenwood D, Bidgood K, Turner M. 1987. A comparison of the responses of staphylococci and streptococci to teicoplanin and vancomycin. J. Antimicrob. Chemother. 20:155-164. http://dx.doi.org/10.1093/jac/20.2.155.
25. Chmara H, Ripa S, Mignini F, Borowski E. 1991. Bacteriolytic effect of teicoplanin. J. Gen. Microbiol. 137:913-919. http://dx.doi.org/10.1099/00221287-137-4-913.
26. Hamburger JB, Hoertz AJ, Lee A, Senturia RJ, McCafferty DG, Loll PJ. 2009. A crystal structure of a dimer of the antibiotic ramoplanin illustrates membrane positioning and a potential lipid II docking interface. Proc. Natl. Acad. Sci. U. S. A. 106:13759-13764. http://dx.doi.org/10.1073/pnas.0904686106.
27. Cudic P, Kranz JK, Behenna DC, Kruger RG, Tadesse H, Wand AJ, Veklich YI, Weisel JW, McCafferty DG. 2002. Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation. Proc. Natl. Acad. Sci. U. S. A. 99:7384-7389. http://dx.doi.org/10.1073/pnas.102192099.
28. Geiger O, Gonzalez-Silva N, Lopez-Lara IM, Sohlenkamp C. 2010. Amino acid-containing membrane lipids in bacteria. Prog. Lipid Res. 49: 46-60. http://dx.doi.org/10.1016/j.plipres.2009.08.002.
29. Sievers S, Ernst CM, Geiger T, Hecker M, Wolz C, Becher D, Peschel A. 2010. Changing the phospholipid composition of Staphylococcus aureus causes distinct changes in membrane proteome and membrane-sensory regulators. Proteomics 10:1685-1693. http://dx.doi.org/10.1002/pmic.200900772.
30. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed, M7-A7. CLSI, Wayne, PA.
31. Peterson LR, Shanholtzer CJ. 1992. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin. Microbiol. Rev. 5:420-432.
32. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline;
33. Sando L, Henriques ST, Foley F, Simonsen SM, Daly NL, Hall KN, Gustafson KR, Aguilar M-I, Craik DJ. 2011. A synthetic mirror image of kalata b1 reveals that cyclotide activity is independent of a protein receptor. Chembiochem 12:2456-2462. http://dx.doi.org/10.1002/cbic.201100450.
34. Gohlke A, Triola G, Waldmann H, Winter R. 2010. Influence of the lipid anchor motif of N-ras on the interaction with lipid membranes: a surface plasmon resonance study. Biophys. J. 98:2226-2235. http://dx.doi.org/10.1016/j.bpj.2010.02.005.
35. Ishizuka-Katsura Y, Wazawa T, Ban T, Morigaki K, Aoyama S. 2008. Biotin-containing phospholipid vesicle layer formed on self-assembled monolayer of a saccharide-terminated alkyl disulfide for surface plasmon resonance biosensing. J. Biosci. Bioeng. 105:527-535. http://dx.doi.org/10.1263/jbb.105.527.
36. Cooper MA, Hansson A, Lofas S, Williams DH. 2000. A vesicle capture sensor chip for kinetic analysis of interactions with membrane-bound receptors. Anal. Biochem. 277:196-205. http://dx.doi.org/10.1006/abio.1999.4389.
37. Chia CSB, Gong Y, Bowie JH, Zuegg J, Cooper MA. 2011. Membrane binding and perturbation studies of the antimicrobial peptides caerin, citropin, and maculatin. Biopolymers 96:147-157. http://dx.doi.org/10.1002/bip.21438.
38. Friedrich CL, Moyles D, Beveridge TJ, Hancock REW. 2000. Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob. Agents Chemother. 44:2086-2092. http://dx.doi.org/10.1128/AAC.44.8.2086-2092.2000.
39. Cotroneo N, Harris R, Perlmutter N, Beveridge T, Silverman JA. 2008. Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2223-2225. http://dx.doi.org/10.1128/AAC.01410-07.
40. Belley A, Harris R, Beveridge T, Parr T, Jr, Moeck G. 2009. Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Antimicrob. Agents Chemother. 53:800-804. http://dx.doi.org/10.1128/AAC.00603-08.
41. Barry AL, Pfaller MA, Fuchs PC. 1993. Ramoplanin susceptibility testing criteria. J. Clin. Microbiol. 31:1932-1935.
42. Jiang WL, Wanner J, Lee RJ, Bounaud PY, Boger DL. 2003. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J. Am. Chem. Soc. 125:1877-1887. http://dx.doi.org/10.1021/ja0212314.
43. Rew Y, Shin D, Hwang I, Boger DL. 2004. Total synthesis and examination of three key analogues of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. J. Am. Chem. Soc. 126:1041-1043. http://dx.doi.org/10.1021/ja039671y.
44. Kenny MT, Brackman MA. 1994. Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs. J. Clin. Microbiol. 32:1364-1365.
45. French GL. 2010. The continuing crisis in antibiotic resistance. Int. J. Antimicrob. Agents 36 (Suppl 3) :3-7. http://dx.doi.org/10.1016/S0924-8579(10)70003-0.
46. Brumfitt W, Maple PAC, Hamiltonmiller JMT. 1990. Ramoplanin versus methicillin-resistant Staphylococcus aureus: in vitro experience. Drug Exp. Clin. Res. 16:377-383.
47. Aeschlimann JR, Hershberger E, Rybak MJ. 1999. Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1914-1918.
48. Singh SR, Bacon AE, III, Young DC, Couch KA. 2009. In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4495-4497. http://dx.doi.org/10.1128/AAC.00237-09.
49. Fernandez DI, Gehman JD, Separovic F. 2009. Membrane interactions of antimicrobial peptides from Australian frogs. Biochim. Biophys. Acta 1788:1630-1638. http://dx.doi.org/10.1016/j.bbamem.2008.10.007.
50. Zhang JI, Talaty N, Costa AB, Xia Y, Tao WA, Bell R, Callahan JH, Cooks RG. 2011. Rapid direct lipid profiling of bacteria using desorption electrospray ionization mass spectrometry. Int. J. Mass Spectrom. 301:37-44. http://dx.doi.org/10.1016/j.ijms.2010.06.014.
51. Stenberg E, Persson B, Roos H, Urbaniczky C. 1991. Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins. J. Colloid Interface Sci. 143:513-526. http://dx.doi.org/10.1016/0021-9797(91)90284-F.
52. Cooper MA, Fiorini MT, Abell C, Williams DH. 2000. Binding of vancomycin group antibiotics to D-alanine and D-lactate presenting self-assembled monolayers. Bioorg. Med. Chem. 8:2609-2616. http://dx.doi.org/10.1016/S0968-0896(00)00184-X.
53. Lohner K, Blondelle SE. 2005. Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb. Chem. High Throughput Screen. 8:241-256. http://dx.doi.org/10.2174/1386207053764576.
54. Scherer K, Wiedemann I, Ciobanasu C, Sahl H-G, Kubitscheck U. 2013. Aggregates of nisin with various bactoprenol-containing cell wall precursors differ in size and membrane permeation capacity. Biochim. Biophys. Acta 1828:2628-2636. http://dx.doi.org/10.1016/j.bbamem.2013.07.014.
55. Wu M, Maier E, Benz R, Hancock REW. 1999. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry 38: 7235-7242. http://dx.doi.org/10.1021/bi9826299.
56. Zhang LJ, Dhillon P, Yan H, Farmer S, Hancock REW. 2000. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3317-3321. http://dx.doi.org/10.1128/AAC.44.12.3317-3321.2000.
57. Walsh CT, Fisher SL, Park IS, Prahalad M, Wu Z. 1996. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol. 3:21-28. http://dx.doi.org/10.1016/S1074-5521(96)90079-4.
58. Silverman JA, Perlmutter NG, Shapiro HM. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544. http://dx.doi.org/10.1128/AAC.47.8.2538-2544.2003.
59. Paiva AD, Breukink E, Mantovani HC. 2011. Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5. Antimicrob. Agents Chemother. 55:5284-5293. http://dx.doi.org/10.1128/AAC.00638-11.
60. Matias VRF, Beveridge TJ. 2007. Cryo-electron microscopy of cell division in Staphylococcus aureus reveals a mid-zone between nascent cross walls. Mol. Microbiol. 64:195-206. http://dx.doi.org/10.1111/j.1365-2958.2007.05634.x.
61. Touhami A, Jericho MH, Beveridge TJ. 2004. Atomic force microscopy of cell growth and division in Staphylococcus aureus. J. Bacteriol. 186: 3286-3295. http://dx.doi.org/10.1128/JB.186.11.3286-3295.2004.
62. Sudhahar CG, Haney RM, Xue Y, Stahelin RV. 2008. Cellular membranes and lipid-binding domains as attractive targets for drug development. Curr. Drug Targets 9:603-613. http://dx.doi.org/10.2174/138945008785132420.
63. Andrushchenko VV, Aarabi MH, Nguyen LT, Prenner EJ, Vogel HJ. 2008. Thermodynamics of the interactions of tryptophan-rich cathelicidin antimicrobial peptides with model and natural membranes. Biochim. Biophys. Acta 1778: 1004-1014. http://dx.doi.org/10.1016/j.bbamem.2007.12.022.
64. Brotz H, Josten M, Wiedemann I, Schneider U, Gotz F, Bierbaum G, Sahl HG. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30:317-327. http://dx.doi.org/10.1046/j.1365-2958.1998.01065.x.
65. Breukink E, de Kruijff B. 2006. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5:321-332. http://dx.doi.org/10.1038/nrd2004.
66. Gehman JD, Luc F, Hall K, Lee T-H, Boland MP, Pukala TL, Bowie JH, Aguilar M-I, Separovic F. 2008. Effect of antimicrobial peptides from Australian tree frogs on anionic phospholipid membranes. Biochemistry 47:8557-8565. http://dx.doi.org/10.1021/bi800320v.
67. Nam J, Shin D, Rew Y, Boger DL. 2007. Alanine scan of [LDap(2)]ramoplanin A2 aglycon: assessment of the importance of each residue. J.Am.Chem.Soc. 129:8747-8755. http://dx.doi.org/10.1021/ja068573k.
68. Beauregard DA, Williams DH, Gwynn MN, Knowles DJC. 1995. Dimerization and membrane anchors in extracellular of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39:781-785. http://dx.doi.org/10.1128/AAC.39.3.781.
69. Westwell MS, Gerhard U, Williams DH. 1995. Two conformers of the glycopeptide antibiotic teicoplanin with distinct ligand-binding sites. J. Antibiot. (Tokyo) 48:1292-1298. http://dx.doi.org/10.7164/antibiotics.48.1292.
70. Cudic P, Behenna DC, Kranz JK, Kruger RG, Wand AJ, Veklich YI, Weisel JW, McCafferty DG. 2002. Functional analysis of the lipogly-codepsipeptide antibiotic ramoplanin. Chem. Biol. 9:897-906. http://dx.doi.org/10.1016/S1074-5521(02)00191-6.
71. Mechler A, Praporski S, Atmuri K, Boland M, Separovic F, Martin LL. 2007. Specific and selective peptide-membrane interactions revealed using quartz crystal microbalance. Biophys. J. 93:3907-3916. http://dx.doi.org/10.1529/biophysj.107.116525.
72. Kemper MA, Urrutia MM, Beveridge TJ, Koch AL, Doyle RJ. 1993. Proton motive force may regulate cell wall-associated enzymes of Bacillus subtilis. J. Bacteriol. 175:5690-5696.
73. Benech RO, Kheadr EE, Lacroix C, Fliss I. 2002. Antibacterial activities of nisin Z encapsulated in liposomes or produced in situ by mixed culture during cheddar cheese ripening. Appl. Environ. Microbiol. 68:5607-5619. http://dx.doi.org/10.1128/AEM.68.11.5607-5619.2002.